- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04292301
MRI Assessing Clinical Usability of STrategically Acquired Gradient Echo on Human Participants (STAGE)
June 2, 2022 updated by: SpinTech, Inc.
Multi-Centered Study Comparison of Output Images From STrategically Acquired Gradient Echo to Conventional 1.5 T and 3.0 T Magnetic Resonance Images and Assessing Their Clinical Usability on Human Participants
The study's purpose is to validate STAGE images and, when applicable, their equivalence to conventional MRI through an assessment by a trained certified neuroradiologist in a clinical setting.
For STAGE images without conventional equivalent, the neuroradiologist will determine if their contrasts, intensities, and quality are sufficient and meet expectations for images used in radiological reads of the brain.
The study is a multi-center study in which STAGE can be assessed at sites with different MRI manufacturers and field strengths.
Site names will be made available to the collaborators and participants.
The sponsor is based out of Michigan, while participating sites may be located in other states.
Any funding for the study will come from an industry source, SpinTech, Inc.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The scope of the study includes the acquisition of MR images from a specified MR manufacturer, the installation of the STAGE device at the clinical site, the subsequent processing of the acquired MR images, and their evaluation by neuroradiologists. The follow section will summarize the key procedures which are involved in this study.
- Participants will be enrolled as study subjects per IRB approved protocol and informed consent.
- The STAGE device will be installed at the clinical site. The installation of the Investigational STAGE module requires it to be labeled for Investigational Use Only, per FDA requirements. It requires an available power source and live Ethernet connection. STAGE is connected to the PACS via a node which requires the AE title and an assigned IP address. The node will only accept images which meet the STAGE protocol requirements and any other images are not used. After the images are processed and sent back to the PACS system, all data are purged from the STAGE module. A log is kept of which data was processed which can be viewed through the assigned IP within a web browser. All images under the study protocol shall be labeled "For Investigational Device Use Only".
- The PI and Co-Investigators will be trained on the use of installed STAGE investigational device. This will include a review of the installation and user manuals written as documentation under the FDA regulated development process. Documentation of the training process will be documented with data workflow and output images being presented.
- After these steps the clinical study collection of MR images will begin. Since a primary aim of STAGE is to reduce acquisition times while generating a wealth of contrasts from the dataset, additional conventional MR images will be acquired including but not limited to: T1W, Susceptibility Weighted Images (SWI), Magnetic Resonance Angiography (MRA), and Spin Density Weighted (PDW). The patient's time in the magnet will be kept under 40 minutes. The STAGE protocol is available for Siemens, GE, Philips, and Canon/Toshiba magnets at both 1.5T and 3.0T field strengths. The processed STAGE images will be sent back to the PACS system where they remain within the participant's scan folder and are clearly labeled. They can then be viewed at an integrated workstation.
- The study data will then be collected on Case Report Forms to record the response from the reading radiologist as well as the documented acquisition times for the STAGE protocol and the standard of care acquisition times used within that clinical setting (control arm of study). Prospective data will include imaging as well as questionnaire/survey with the radiologist to evaluate the performance of STAGE and its outputs. The study will not consist of retrospective data.
- Clinical study completions and closeout. At the conclusion of the study, STAGE will be removed from the site by a trained technician and all data from the study will be purged from the PACS. A checklist will be documented to show that all measurable clinical response metrics have been recorded and that the study has successfully contributed its intended aims while following IRB and FDA regulations for clinical studies.
Study Type
Interventional
Enrollment (Actual)
92
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Loma Linda, California, United States, 92354
- Loma Linda University Health
-
Los Gatos, California, United States, 95032
- Insight Imaging - Center for Diagnostic Imaging
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa
-
-
Oklahoma
-
Edmond, Oklahoma, United States, 73013
- Summit Medical Center
-
-
Texas
-
Dallas, Texas, United States, 75390
- University of Texas Southwestern Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 80 years (ADULT, OLDER_ADULT, CHILD)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects 6-80 years of age, inclusive.
- Literate in English
- No contraindications to MR
- Not claustrophobic
Exclusion Criteria:
- Subject has diffuse white matter disease or leukoaraiosis.
- Participant, or if participant is under 18 years of age, participant's parent or guardian unable to read and sign an informed consent.
- Women who are pregnant or breast-feeding.
- Those with major surgery within the past eight weeks or scheduled surgery within 30 days.
- Chronic back pain or inability to lie still for 5 minutes or more.
- History of drug or alcohol abuse.
- Individuals who exceed 28 BMI or 320 lbs.
- Individual whose girth exceeds the magnetic bore.
- Direct employee or student of the PI.
- Participants belong to a vulnerable group.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: STrategically Acquired Gradient Echo (STAGE)
STAGE Inputs are flow compensated 3D gradient echo MR images acquired at optimal parameters which are used to calculate multiple contrasts for brain imaging.
All subjects within the study are imaged using both a conventional MR protocol and STAGE protocol.
|
The STAGE package uses conventional 3D gradient echo MR, its magnitude and phase, collected at set parameters which allow for the reconstruction of multiple MR datasets which results in decreased acquisition time, equivalency to conventional MR, and the decrease in scan time allows for a higher standard of wealth within the data acquired.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Numeric Rating Scale of Clinical Usability Assessment of STAGE Outputs
Time Frame: Baseline Only
|
Reading radiologists responses on the clinical usability of STAGE Outputs based on image quality using a numeric rating scale of 1 to 5 with: 1=unacceptable, 2=poor, 3=acceptable, 4=good, 5=excellent.
Scores of 3 or greater are considered clinically usable.
|
Baseline Only
|
Review of STAGE Outputs for Artifact and Image Contrast
Time Frame: Baseline Only
|
Reading radiologist and image analyst responses on the clinical usability of STAGE Outputs based on image quality using a yes/no criteria for presence of novel or accentuated imaging artifact.
Hardware or participant artifact contributions (i.e.
coil sensitivity and motion) were not considered unless noted as increased due to the STAGE method.
Each image series was evaluated for the presence of artifact.
The total count of the artifacts reported across series evaluated in the study is reported.
|
Baseline Only
|
Review of STAGE Outputs for Expected Brain Structural Appearance
Time Frame: Baseline Only
|
Reading radiologists responses on the clinical usability of STAGE Outputs based on image appearance of specified brain structures using pass/fail criteria.
Expected brain contrast between tissue types will vary depending on the output reviewed (i.e.
T1W, PDW, SWI).
The behavior of tissue contrasts (i.e.
white matter vs gray matter) should also demonstrate standard anatomic contrast (T1W, PDW, SWI) as well quantitative ratio for maps (T2*MAP, R2*MAP, SWIM, T1MAP, PDMAP).
For artery/vein appearance, STAGE T1W, T1MAP and PD MAP were not evaluated due to artery/vein not appearing in the image contrasts.
For GM/WM/CSF, the MRA, pSWIM and mpSWIM were not evaluated due to the anatomic contrast not appearing in the image contrasts.
For calcium/iron appearance, T1WE, T1MAP, PDMAP, MRA, and DIR were not evaluated due to the calcium/iron not appearing in the image contrasts.
|
Baseline Only
|
Evaluation of STAGE Image Processing Times
Time Frame: Baseline Only
|
Review of the recorded processing times for the STAGE module to accept and process STAGE inputs and to export them back to the PACS as STAGE outputs.
|
Baseline Only
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Douglas P Beall, MD, Summit Medical Center
- Principal Investigator: Murray A Solomon, MD, Center For Diagnostic Imaging
- Principal Investigator: Vincent Magnotta, MD, University of Iowa
- Principal Investigator: Karen Tong, MD, Loma Linda University Health
- Principal Investigator: Frank Yu, MD, University of Texas
- Principal Investigator: Letterio Politi, MD, University of Massachusetts, Worcester
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Haacke EM, Chen Y, Utriainen D, Wu B, Wang Y, Xia S, He N, Zhang C, Wang X, Lagana MM, Luo Y, Fatemi A, Liu S, Gharabaghi S, Wu D, Sethi SK, Huang F, Sun T, Qu F, Yadav BK, Ma X, Bai Y, Wang M, Cheng J, Yan F. STrategically Acquired Gradient Echo (STAGE) imaging, part III: Technical advances and clinical applications of a rapid multi-contrast multi-parametric brain imaging method. Magn Reson Imaging. 2020 Jan;65:15-26. doi: 10.1016/j.mri.2019.09.006. Epub 2019 Oct 16.
- Wang Y, Chen Y, Wu D, Wang Y, Sethi SK, Yang G, Xie H, Xia S, Haacke EM. STrategically Acquired Gradient Echo (STAGE) imaging, part II: Correcting for RF inhomogeneities in estimating T1 and proton density. Magn Reson Imaging. 2018 Feb;46:140-150. doi: 10.1016/j.mri.2017.10.006. Epub 2017 Oct 20.
- Chen Y, Liu S, Wang Y, Kang Y, Haacke EM. STrategically Acquired Gradient Echo (STAGE) imaging, part I: Creating enhanced T1 contrast and standardized susceptibility weighted imaging and quantitative susceptibility mapping. Magn Reson Imaging. 2018 Feb;46:130-139. doi: 10.1016/j.mri.2017.10.005. Epub 2017 Oct 19.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 30, 2020
Primary Completion (ACTUAL)
January 7, 2021
Study Completion (ACTUAL)
January 7, 2021
Study Registration Dates
First Submitted
February 25, 2020
First Submitted That Met QC Criteria
February 27, 2020
First Posted (ACTUAL)
March 3, 2020
Study Record Updates
Last Update Posted (ACTUAL)
June 28, 2022
Last Update Submitted That Met QC Criteria
June 2, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Other Study ID Numbers
- CP-STAGE-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on MRI
-
Centre Hospitalier Universitaire de NīmesRecruiting
-
PfizerCompletedMRI SedationUnited States, Japan
-
University of UtahWithdrawnMRI ScansUnited States
-
Rennes University HospitalRecruiting
-
Fondation Ophtalmologique Adolphe de RothschildRecruiting
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
University of LiegeUnknown
-
Assistance Publique - Hôpitaux de ParisNot yet recruiting
Clinical Trials on STrategically Acquired Gradient Echo (STAGE)
-
NYU Langone HealthRecruitingBreast CancerUnited States
-
Hospices Civils de LyonRecruitingKidney Cancer | Head and Neck Cancer | Glioblastoma | Prostate Cancer | Cervix CancerFrance
-
Rennes University HospitalMinistry of Health, FranceCompletedHepatitis B | Hepatitis C | Iron Overload | Metabolic Syndrome X | Alcohol AbuseFrance, Spain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Acute Promyelocytic Leukemia With PML-RARAUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingRecurrent Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Refractory Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Lymphoma | Clonal Cytopenia of Undetermined Significance | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsUnited States